MAKE APPOINTMENT

Merck and Moderna Prepare FDA Filing for Personalized mRNA Melanoma Vaccine Paired with Keytruda After Phase 3 Results

by | Oct 20, 2026 | Uncategorized | 0 comments

Merck and Moderna are preparing to seek FDA approval for a personalized mRNA melanoma vaccine used with Keytruda. No filing date has been set.

Submit a Comment

Your email address will not be published. Required fields are marked *